PHILADELPHIA--(BUSINESS WIRE)--May 22, 2006--Lannett Company, Inc. (AMEX:LCI - News), a manufacturer of generic pharmaceuticals, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its supplemental Abbreviated New Drug Application (sANDA) for Probenecid Tablets 500 mg, USP. According to NDC Health (now known as Wolters Kluwar), total sales in 2005 of Probenecid were approximately $26.0 million. The company expects to commence marketing this product shortly.
